Amgen Inc. (FRA:AMG)
241.95
-0.30 (-0.12%)
Last updated: May 14, 2025
Amgen Revenue
Amgen had revenue of $8.15B USD in the quarter ending March 31, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.13B, up 15.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.13B
Revenue Growth
+15.56%
P/S Ratio
3.99
Revenue / Employee
$1.22M
Employees
28,000
Market Cap
125.90B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 76.54B |
Deutsche Telekom AG | 118.43B |
Allianz SE | 107.35B |
Rheinmetall AG | 10.48B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.87B |
Siemens Energy AG | 37.44B |
Merck KGaA | 21.16B |
Amgen News
- 2 days ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 3 days ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 3 days ago - European pharma stocks follow Asia peers down as Trump moves to cut prices - Reuters
- 5 days ago - AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 7 days ago - Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI - GlobeNewsWire
- 7 days ago - Amgen’s Tepezza becomes first U.K.-medicine approved for adults with thyroid eye disease - Seeking Alpha
- 7 days ago - What the Options Market Tells Us About Amgen - Benzinga
- 7 days ago - Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom - Business Wire